1. Home
  2. DVAX vs CVE Comparison

DVAX vs CVE Comparison

Compare DVAX & CVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • CVE
  • Stock Information
  • Founded
  • DVAX 1996
  • CVE 2009
  • Country
  • DVAX United States
  • CVE Canada
  • Employees
  • DVAX N/A
  • CVE N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • CVE Oil & Gas Production
  • Sector
  • DVAX Health Care
  • CVE Energy
  • Exchange
  • DVAX Nasdaq
  • CVE Nasdaq
  • Market Cap
  • DVAX 1.3B
  • CVE 23.5B
  • IPO Year
  • DVAX 2004
  • CVE N/A
  • Fundamental
  • Price
  • DVAX $9.36
  • CVE $17.16
  • Analyst Decision
  • DVAX Buy
  • CVE Strong Buy
  • Analyst Count
  • DVAX 4
  • CVE 3
  • Target Price
  • DVAX $26.50
  • CVE $23.33
  • AVG Volume (30 Days)
  • DVAX 1.9M
  • CVE 15.8M
  • Earning Date
  • DVAX 11-06-2025
  • CVE 10-30-2025
  • Dividend Yield
  • DVAX N/A
  • CVE 3.10%
  • EPS Growth
  • DVAX N/A
  • CVE N/A
  • EPS
  • DVAX N/A
  • CVE 1.05
  • Revenue
  • DVAX $316,268,000.00
  • CVE $38,310,383,744.00
  • Revenue This Year
  • DVAX $23.23
  • CVE N/A
  • Revenue Next Year
  • DVAX $16.57
  • CVE N/A
  • P/E Ratio
  • DVAX N/A
  • CVE $16.33
  • Revenue Growth
  • DVAX 26.66
  • CVE N/A
  • 52 Week Low
  • DVAX $9.21
  • CVE $10.23
  • 52 Week High
  • DVAX $14.63
  • CVE $18.62
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 32.99
  • CVE 65.65
  • Support Level
  • DVAX $9.51
  • CVE $15.80
  • Resistance Level
  • DVAX $9.94
  • CVE $17.15
  • Average True Range (ATR)
  • DVAX 0.29
  • CVE 0.45
  • MACD
  • DVAX -0.07
  • CVE 0.01
  • Stochastic Oscillator
  • DVAX 12.31
  • CVE 91.28

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About CVE Cenovus Energy Inc

Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.

Share on Social Networks: